Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
Tushar Pandey, Editorial Board Member at Journal of Cancer Chemotherapy, shared on LinkedIn:
”Managing Thrombotic Thrombocytopenic Purpura (TTP):
Where Speed, Systems, and Specialized Expertise Save Lives
The patient presented in a critically ill state with:
- Altered sensorium
- Generalized seizures
- Jaundice
Recognizing the severity, a rapid and comprehensive clinical, radiological, and laboratory evaluation was initiated within hours of presentation.
This enabled prompt diagnosis of Thrombotic Thrombocytopenic Purpura (TTP), a life-threatening hematological emergency.
What made the difference
- Immediate initiation of therapeutic plasma exchange (PLEX)
- High-dose immunosuppression
- Early integration of immunotherapy
- Continuous neurological and biochemical monitoring
- ICU-based, hematology-led decision-making
This was not reactive medicine.
This was planned, systematic execution by a world-class hematology team.
Multidisciplinary Excellence
Successful TTP management is never a single-department effort. I acknowledge the outstanding active participation of:
- Nephrology
- Neurology
- Critical Care and Transfusion teams, providing round-the-clock support
All teams worked in perfect synchrony from the first hour.
Outcome
Despite a high-risk and stormy course, the patient improved steadily. Platelet counts recovered, hemolysis resolved, neurological status stabilized, and she was discharged home safely.
What this case represents
World-class hematology emergency care
Expertise in ICU-level hematological crises
Early diagnosis plus early treatment equals survival
International-standard Hematology, Hemato-Oncology, and BMT care in Haldwani
As Head of Hematology, Hemato-Oncology, and BMT at Raghav Institute of Hematology, Hemato-Oncology and BMT, Haldwani, I can confidently say this case reinforces one truth:
When expertise leads early, lives are saved.”
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC